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(ACC-AHA) Task Force on Practice Guidelines (Stone NJ et al, Circulation
2013 [E-pub ahead of print] doi: 10.1161/01.cir.0000437738.63853.7a).
These new guidelines represent a signiﬁcant departure from previous recom-
mendations that promoted speciﬁc lipid-level goals for patients that
depended on level of risk. The new guidelines rely heavily on randomized,
controlled trials involving ﬁxed doses of statin medications in patients at risk
for atherosclerotic cardiovascular disease. Four subgroups of patients were
identiﬁed where beneﬁts of statins outweigh risk. These included (1) those
with clinically evident atherosclerotic cardiovascular disease; (2) primary
low-density lipoprotein (LDL) cholesterol levels $190 mg/dL; (3) patients
with type 1 or type 2 diabetes and LDL cholesterol levels $70 mg/dL; and
(4) patients with a 10-year risk of atherosclerotic cardiovascular disease of at
least 7.5% and an LDL cholesterol level $70 mg/dL. In addition, the new
guidelines identify patients for whom data do not support statin therapy.
These include those aged$75 years unless clinical atherosclerotic cardiovas-
cular disease is present, those with a need for hemodialysis, or patients with
New York Heart Association class II, III, or IV heart failure. In addition, the
panel noted that there was no evidence to support use of nonstatin choles-
terol-lowering drugs combined with statin therapy or in statin-intolerant
patients.
Comment: Adherence to the new guidelines will result in consider-
able changes in practice patterns that include avoidance of cholesterol-
lowering therapy in certain patient groups and elimination of routine
assessments of LDL cholesterol levels in patients receiving statin therapy
because target levels are no longer emphasized. Additional changes
include avoidance of nonstatin LDL cholesterol-lowering agents, more
conservative use of statins in patients aged >75 years, and diminished
use of surrogate markers, such as C-reactive protein or calcium scores,
for selection of patients for statin therapy. Finally, the use of a new risk
calculator in the new guidelines is likely to target larger numbers of
patients for statin therapy.
Screening for Peripheral Artery Disease and Cardiovascular Disease
Risk Assessment With the Ankle-Brachial Index in Adults: U.S.
Preventive Services Task Force Recommendation Statement
Moyer VA, and the U.S. Preventive Services Task Force. Ann Intern Med
2013; 159:342-8.
Conclusions: Current evidence is insufﬁcient to assess the balance of
beneﬁts and harms for screening for peripheral arterial disease (PAD) and
cardiovascular disease (CVD) risk assessment with ankle-brachial index
(ABI) in adults.
Summary: The U.S. Preventive Services Task Force (USPSTF) makes
recommendations about effectiveness of speciﬁc preventive care services for
patients without disease-related symptoms. Recommendations are based on
balance of beneﬁts and harm of the potential testing modality with respect
to the disease process undergoing evaluation. With respect to PAD, early
detection of PAD in asymptomatic patients is primarily considered because
subsequent treatment may reduce overall CVD. However, the USPSTF
found no evidence that screening for treatment of PAD in asymptomatic pa-
tients can provide clinically important beneﬁts. In fact, one randomized trial
found that aspirin did not reduce CVD events in patients with low ABI
(Fowkes FG et al, JAMA 2010;303:841-8). The same trial found that
low-dose aspirin treatment in asymptomatic patients with a low ABI might
actually increase bleeding. Additional harms considered by the USPSTF for
screening ABI included false-positive results, with the potential of subse-
quent exposure to gadolinium or a contrast agent if additional studies are
used to conﬁrm diagnoses. In addition, patient anxiety and opportunity
costs were also considered potential harms. Additional potential harms
included the use of unnecessary medications (or higher doses) and the
resulting adverse effects of additional medications or increased medication
dosages. Most of these potential harms are downstream harms because there
is little potential harm associated with conducting the ABI examination it-
self. This study follows two previous recommendations by the USPSTF
against screening for PAD, the ﬁrst in 1996 and the second in 2005. The
current study focused on broader CVD outcomes than previous reviews
and speciﬁcally focused on resting ABI as the sole screening method.
Although the USPSTF found evidence that ABI is a reliable screening
test for PAD, the ultimate conclusion was that the evidence to support treat-
ment based on this screening test is inadequate and that there were no
studies addressing harms of screening.
Comment: Detection of asymptomatic peripheral arterial disease may
identify patients at risk for other types of CVD other than just PAD. How-
ever, evidence directly supporting this supposition is lacking. “Therefore the
USFPSTF concludes that the evidence on the balance of beneﬁts and harms
of screening is lacking.” One must also consider that many patients with
asymptomatic low ABIs may never develop clinical signs or symptoms of
CVD and yet if treated on the basis of the low ABI would be subject tothe harms of testing and subsequent treatments. With the exception of
screening for abdominal aortic aneurysm, screening for any form of PVD
remains controversial.
Carotid Plaque MRI and Stroke Risk: A Systematic Review and Meta-
analysis
Gupta A, Baradaran H, Schweitzer AD, et al. Stroke 2013;44:3071-7.
Conclusions: Dedicated magnetic resonance imaging (MRI) of pla-
que composition offers stroke risk information beyond measurement of
luminal stenosis in carotid atherosclerotic disease.
Summary: Stenosis severity is widely used as a marker for stroke risk
in patients with atherosclerotic carotid disease. However, evidence also sug-
gests plaque composition can also predict stroke risk independent of stenosis
severity (den Hartog AG et al, Eur J Vasc Endovasc Surg 2013;45:7-21).
MRI measurements of plaque composition may help characterize carotid
plaques with respect to stroke risk. However, individual studies have been
relatively small, and it is unclear whether differences in risk proﬁles of spe-
ciﬁc plaque components, such as intraplaque hemorrhage, lipid-rich necrotic
core, or thinning/rupture of the ﬁbrous cap, contribute differentially to
stroke risk. The authors therefore performed a systematic review and
meta-analysis to evaluate whether MRI of plaque composition is a predictor
of ipsilateral ischemic stroke or transient ischemic attack (TIA) in carotid
atherosclerotic disease. A comprehensive literature search evaluated the as-
sociation of carotid plaque composition on MRI with ischemic outcomes.
Included studies were cohort studies examining intraplaque hemorrhage,
lipid-rich necrotic core, or thinning/rupture of the ﬁbrous cap with a
mean follow-up of $1 month and an outcome measure of ipsilateral stroke
or TIA. A meta-analysis using a random-effects model assessing study het-
erogeneity and publication biases was performed. The authors screened
3436 articles, and nine studies with a total of 779 subjects met eligibility
for systematic review. Ratios for intraplaque hemorrhage, lipid-rich necrotic
core, and thinning/rupture of the ﬁbrous cap as predictors of subsequent
stroke/TIA were 4.59 (95% conﬁdence interval [CI], 2.91-7.24), 3.00
(95% CI, 1.51-5.95), and 5.93 (95% CI, 2.65-13.20), respectively. There
was no signiﬁcant heterogeneity or publication bias in the three main
meta-analyses performed.
Comment: One possible conclusion of this article, given the number
of articles potentially available for inclusion in this study and the small num-
ber subsequently selected for systematic review, is that there must be
remarkable limitations of the current literature on MRI plaque characteriza-
tion. Therefore, the use of carotid plaque MRI to select high-risk groups
potentially beneﬁting from carotid intervention remains quite problematic
at this point. The study does point out that the MRI variables of intraplaque
hemorrhage, lipid-rich necrotic core, and thinning of the ﬁbrous cap are tar-
gets for future research.
Doxycycline for Stabilization of Abdominal Aortic Aneurysms: A
Randomized Trial
Meijer CA, Stigmen T, and the Pharmaceutical Aneurysm Stabilization Trial
Study Group. Ann Intern Med. 2013;159:815-23.
Conclusions: Doxycycline therapy for 18 months does not reduce
aneurysm growth and does not inﬂuence need for aneurysm repair or
time to repair.
Summary: Matrix metalloproteinases (MMPs) appear to be involved
in abdominal aortic aneurysm (AAA) pathogenesis and pathophysiology.
Doxycycline is a nonspeciﬁc MMP inhibitor and has been shown to decrease
AAA formation and progression in preclinical models of aneurysm disease
(Bergqvist D, Eur J Vasc Endovasc Surg 2011;41:663-7; and Dodd BR
et al, Curr Vasc Pharmacol 2011;9:4-8). In addition, a small study of 3
months of doxycycline reported reduced aneurysm growth 6 to 12 months
later (Mosorin M et al, J Vasc Surg 2001;34:6-10). Finally, a safety trial of
6 months of doxycycline treatment reported that “the observed rate of
aneurysm growth compared favorably with that described in natural history
studies of aneurysm growth” (Baxter BT et al, J Vasc Surg 2002;36:1-12).
Other medical therapies, most prominently b-blockers, have been consid-
ered for medical management of disease but have not been conclusively
demonstrated to reduce progression of AAAs. Currently, doxycycline is
considered to be the lead candidate for potential pharmaceutical stabiliza-
tion of AAAs. The purpose of this study was to test whether doxycycline
inhibits AAA progression in humans. This was a randomized placebo-
controlled, double-blind trial conducted in 14 Dutch hospitals. The study
recruited 286 patients with small AAAs and randomized 144 to daily doses
of 100 mg doxycycline and 142 to placebo for 18 months. The two groups
were well balanced with respect to baseline demographic and clinical char-
acteristics. The primary outcome measure was aneurysm growth at 18
months, as estimated by repeated single-observer ultrasound study. Second-
ary outcome measures included aneurysm growth at 12 months and need
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growth compared with the control group. In fact, there was a small increase
in aneurysm growth of 4.1 mm (95% conﬁdence interval [CI], 3.6-4.5 mm)
in the doxycycline group vs 3.3 mm (95% CI, 2.8-3.7 mm) in the control
group at 18 months. The difference in diameter growth was 0.8 mm
(95% CI, 0.1-1.4 mm; P ¼ .016). Twenty-one patients receiving doxycy-
cline and 22 receiving placebo had elective surgical repair. Kaplan-Meier es-
timates for elective surgical repair were 16.1% for those receiving
doxycycline and 16.5% receiving placebo; difference, 0.4% (95% CI,
9.3% to 8.5%; P ¼ .83). Time to aneurysm repair was also similar in the
groups (P ¼ .92).
Comment: One of the holy grails of vascular disease is a pill to prevent
development of AAAs in patients at risk or slow progression of the AAA in
those with small aneurysms. As such, the results of this study are disap-
pointing, because doxycycline has been considered the leading candidate
for medical management of aortic aneurysm disease. There is currently in
the United States a National Institute of Health-sponsored smaller trial of
doxycycline, using twice the dose of doxycycline used in the Dutch trial,
for management of small AAAs. The results of this study will not likely be
available for several years. Apparently, however, one needs to consider the
possibility that our current understanding of the biochemical mechanisms
of aneurysm formation may be insufﬁcient to develop a precisely targeted
pharmacologic intervention.
A Randomized Trial of Genotype-Guided Dosing of Warfarin
Pirmohamed M, Burnside G, Eriksson N, and EU-PACT Group. N Engl J
Med 2013;369:2294-303
Conclusions: Pharmacogenetic-based dosing is associated with a
higher percentage of time in therapeutic international normalized ratio
(INR) range than standard dosing during initiation of warfarin therapy.
Summary: Warfarin has a wide variation of dosages needed to achieve
relatively narrow therapeutic indices. This variation can be due to insufﬁ-
cient or excessive anticoagulation. Polymorphisms in two genes, CYP2C9
(involved in the metabolism of the pharmacologically more potent S-enan-
tiomer of warfarin) and VKORC1 (involved in the vitamin K cycle), in com-
bination with age and body surface area, are known to account forw50% of
the variability in the individual daily dose requirements for warfarin (John-
son JA et al, Clin Pharmacol Ther 2011;90:625-9; and Yang J et al, Int J
Cardiol 2013;168:4234-43). Indeed, the U.S. Food and Drug Administra-
tion changed the drug label for warfarin to include the statement “The pa-
tient’s CYP2C9 and VKORC1 genotype information, when available, can
assist in selection of the starting dose for warfarin.” (Finkelman BS et al,
J Am CollCardiol 2011;57:612-8). However, lack of data from randomized
trials has led to the fact that genotyping before a prescription of warfarin is
not recommended in clinical practice guidelines (Holbrook A et al, Chest
2012;141(Suppl):e152-84S). There have been prospective studies and ran-
domized trials that failed to show genotyping improves anticoagulation con-
trol, but despite these, a recent study also showed that genotype-guided
dosing led to superior control of anticoagulation (Anderson JL et al, Circu-
lation 2012;125:1997-2005). In this study, the authors prospectively
compared the effect of genotype-guided dosing with that of standard dosing
on anticoagulation control in patients starting warfarin therapy. This was a
multicenter, randomized, control trial involving patients with atrial ﬁbrilla-
tion or venous thromboembolism. Genotyping for CYP2C9*2, CYP2C9*3,
and VKORC1 (e1639G/A) was performed using a point-of-care test. For
patients assigned to the genotype-guided group, warfarin doses were pre-
scribed according to pharmacogenetic-based algorithms for the ﬁrst 5
days. Patients in the standard-dosing group (controls) received a 3-day
loading-dose regimen. After the initiation period, treatment management
of all patients was according to routine clinical practice. The primary
outcome measure was the percentage of time in the therapeutic range,
with 2.0 to 3.0 the goal for the INR during the ﬁrst 12 weeks after initiation
of warfarin therapy. The study recruited 455 patients, and 227 were
randomly assigned to the genotype-guided group and 228 to the control
group. The mean percentage of time in the therapeutic range was 67.4%
in the genotype-guided group compared with 60.3% in the control group
(adjusted difference, 7.0 percentage points; 95% conﬁdence interval, 3.3-
10.6; P < .001). Signiﬁcantly fewer incidences of excessive anticoagulation
(INR $4.0) occurred in the genotype-guided group. Median time to reach
therapeutic INR was 21 days in the genotype-guided group compared with
29 days in the control group (P < .001).
Comment: The trial has a number of weaknesses, including the fact
that the majority of patients are of European ethnic background and the re-
sults can therefore perhaps not be generalized to other ethnic groups. Butmost importantly, the outcome measure was time in so-called therapeutic
range rather than clinical outcome measures of bleeding and thrombosis.
Whether genotype-guided dosing of warfarin therapy can lead to improved
clinical outcomes in a setting outside of a clinical trial remains to be deter-
mined. Indeed, the future role of warfarin anticoagulation in the era where
not all anticoagulation agents will not require monitoring will remain to be
determined. It may be, in the future, that many of the patients included in
this trial will not even be considered for warfarin anticoagulation but will be
preferentially treated by the new oral activated 10a inhibitors.
A Risk Prediction Model for Determining Appropriateness of CEA in
Patients With Asymptomatic Carotid Artery Stenosis
Conrad MF, Kang J, Mukhopadhyay S, et al. Ann Surg 2013;258:534-40.
Conclusions: A scoring system based on the probability of long-term
survival can be used to determine patients most likely to beneﬁt from carotid
endarterectomy (CEA).
Summary: There is considerable controversy about which patients
with asymptomatic carotid stenosis, even high-grade asymptomatic carotid
stenosis, are most likely to beneﬁt from a prophylactic CEA. Indeed, there
are those who believe that asymptomatic carotid stenosis may be best
treated with carotid artery stenting and those who also contend that with
modern medical therapy, asymptomatic carotid stenosis may be best treated
with medical therapy alone. Although it seems intuitive that life expectancy
should be considered in the decision to perform prophylactic CEA, there are
also a number of other variables, such as plaque morphology, degree of ipsi-
lateral carotid stenosis, degree of contralateral carotid stenosis, presence and
number of asymptomatic cerebral infarcts, and patient willingness and ability
to adhere to maximum medical management of atherosclerotic risk factors,
that all can play a role in the decision to perform prophylactic CEA. Indeed,
the authors point out that a recent document from the Society for Vascular
Surgery reported to guide clinical research goals for the next 10 years indi-
cated that optimal management of asymptomatic carotid stenosis was the
top priority (Kraiss LW et al, J Vasc Surg 2013;57:493-500). The goal of
this study was for the authors to create a scoring system to predict 5-year
survival after CEA that would be useful in selecting, or at least helping to
select, patients with asymptomatic carotid stenosis for prophylactic CEA.
The data were based on patients who underwent CEA for severe asymptom-
atic carotid stenosis from 1989 to 2005 at the authors’ institution. Long-
term survival of these patients was determined by a review of hospital
records and the Social Security Death Index. All patients had a potential
for at least 5 years of follow-up. A logistic regression of predictors of survival
at 5 years was performed, and the odds ratios associated with the analysis of
signiﬁcant comorbidities were used to create a scoring system to predict sur-
vival. The scoring system was then validated within the cohort using the
Hosmer-Lemeshow test and a derivation/validation receiver operating
characteristic (ROC) curve. There were 2004 CEA procedures performed
in 1791 patients. The average follow-up was 130 6 49 months. Eighty-
four percent of the patients were hypertensive, 56% had coronary artery dis-
ease, 24% diabetes, and 71% were taking statins. The 30-day stroke rate was
1.1%, and the mortality rate was 0.7%. Actual 5-year survival was 73%.
Predictors of death by logistic regression analysis were age by decade
(odds ratio [OR], 1.8; P < .0001), coronary artery disease (OR, 1.5;
P ¼ .0007), chronic obstructive pulmonary disease (OR, 2.5; P < .0001),
diabetes (OR, 1.7; P < .0001), neck radiation (OR, 2.6; P ¼ .005),
no statin (OR, 2.1; P < .0001), and creatinine >1.5 mg/dL (OR, 2.6;
P < .0001). The variables were then assigned a hierarchal point scoring sys-
tem in accordance with the OR value. The 5-year survival based on the
scoring system was 0 to 5 points, 92.5%, 6 to 8 points, 83.6%; 9 to 11
points, 63.7%; 12 to 14 points, 46.5%; and >15 points, 33.8%. The
Hosmer-Lemeshow test validated the scoring system (P ¼ .26), and there
was no difference in the ROC curves (C statistic, 0.74 vs 0.73).
Comment: Like many surgical series, the data here are highly preju-
diced in that they were derived from patients who actually had a CEA
and were from only a single institution in the Northeast. The potential
for unrecognized confounding variables possibly inﬂuencing the logistic
regression analysis is therefore high. The authors’ data suggest they may
be fairly conservative in selecting their patients, because the highest risk
score for 5-year survival among their patients was 18, with a maximum
possible score of 35. Perhaps the most salient feature of this report is to
demonstrate to our medical colleagues that surgeons really do try to exercise
judgment in their selection of patients for CEA. Selection of patients for
CEA with reasonable life spans is certainly part of that judgment, but
perhaps selection of patients at most risk for disabling stroke or stroke-
related death is also part of that judgment.
